Clinical Trials Browser

Recruiting × ibrutinib × Other hematologic neoplasm × Clear all

NCT06136559 2026-05-26

BELLWAVE-011

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01804686 2026-05-08

CAN3001

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT05963074 2026-05-08

TAILOR

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06299540 2026-05-08

QOLIBRI

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05283720 2026-05-06

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05254743 2026-04-20

BRUIN-CLL-314

Phase 3 Recruiting

LymphoidOther hematologic neoplasm

Hematologic Diseases, Leukemia, Lymphoid, Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT03328078 2026-04-16

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Recurrence, Hematologic Neoplasms

NCT03331198 2026-03-04

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07052695 2025-12-15

Mosunetuzumab for CLL MRD Clearance

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT06958705 2025-11-25

Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03128879 2025-11-21

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06520098 2025-10-14

Benefit VA

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04494503 2025-04-16

Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05694312 2023-12-01

Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL

Phase 2 Recruiting

Classical hematologyLymphoidOther hematologic neoplasm

Anemia, Hemolytic, Autoimmune, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04758975 2023-10-04

VALUABLE

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04908228 2023-10-03

FIGHT

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04771507 2021-02-25

IbruOnOff

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03980002 2019-06-10

BDHCLL001

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell